By Doug Macron

TransDerm, which is developing an siRNA-based treatment for a rare skin disorder, has begun evaluating a variety of different drug-delivery technologies that it hopes will improve the performance of the drug that was observed in a recent phase Ib study.

This week, the company announced that it has formed a research alliance with RXi Pharmaceuticals to evaluate RXi's proprietary RNAi compounds, including its so-called self-delivering rxRNAs, in dermatology models.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.